Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner ; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 101 with placebo , 026 with 1 g idarucizumab ( 74 % reduction ) , 006 with 2 g idarucizumab ( 94 % reduction ) , 002 with 4 g idarucizumab ( 98 % reduction ) , and 001 with 5 g plus 25 g idarucizumab ( 99 % reduction ) .